BackRaia Drogasil S.A. Overview

Raia Drogasil S.A. EBIT

Latest ebit for RADL3.SA: $2.8B, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$818.20M
↑ 0.17% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$2.81B
↓ 1.4% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Raia Drogasil S.A. (RADL3.SA) FAQ

The latest EBIT for RADL3.SA is $2.8B as of September 2026. That compares with $2.9B in the prior-year period — down 1.4% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Raia Drogasil S.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, RADL3.SA's EBIT moved from $2.9B to $2.8B — a 1.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Raia Drogasil S.A.'s operating scale or balance-sheet position.

Against Healthcare companies, RADL3.SA currently prints $2.8B for EBIT, while the sector average sits near $1.9T. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Raia Drogasil S.A.'s growth, margins, and balance sheet.

A EBIT figure of $2.8B for RADL3.SA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting RADL3.SA's EBIT ($2.8B), review year-over-year change from $2.9B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.